Skip to main content
Caplight Logo









Stellaromics

Stellaromics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://stellaromics.com/

Last Round

Series B

Feb 11, 2025

Est. Valuation

$163M

Total Funding Raised

$105M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Stellaromics is a biotechnology company that specializes in 3D spatial multi-omics technology for extracting high-resolution gene expression patterns from thick biological tissue samples.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Usage-Based SaaS

AI Layer

Application

Keywords

spatial transcriptomicsspatial biology3D tissue imaginggene expression analysisspatial multi-omicsPyxatissue profilingsingle cell analysisbiotech equipmenttranslational researchlab automationgenomicsdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Stellaromics Comparables

Compare Stellaromics with similar companies based on industry and business-model similarity.

Stellaromics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Moleculent
88%
Resolve Biosciences
88%
VIZGEN
88%

Stellaromics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 11, 2025
Series ANov 2, 2023

Key People

Founding team and executive leadership

Ye Fu

Chief Scientific Officer and Co-Founder

Founding Team

Todd Dickinson

Chief Executive Officer

Executive Team

Mark Pratt

Chief Technology Officer

Executive Team

Christopher Payton

Fractional CFO

Executive Team

Stellaromics Investors

Notable investors and investment history

Stellaromics investors
InvestorRounds
Stanford UniversitySeries A, Series B
Plaisance Capital ManagementSeries A
Catalyst4Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 10, 2026

    Open roles increased to 11, doubling the trailing average.

  • Jul 27, 2026

    Open roles increased to 9, 3.5x the trailing average.

Stellaromics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Stellaromics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Stellaromics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range58
Year Founded2022
Last FundingFeb 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?